Status:

RECRUITING

Development of LabPatch-alcohol as a Noninvasive Skin Patch to Detect Blood Alcohol Concentrations

Lead Sponsor:

Mclean Hospital

Conditions:

Alcohol Intoxication

Eligibility:

All Genders

21-50 years

Phase:

EARLY_PHASE1

Brief Summary

This study is designed to test LabPatch-alcohol, a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human sub...

Detailed Description

Nanotechnology has the potential to become a powerful tool in addiction medicine. The potential utility for passive, non-invasive wearable alcohol monitors is great and could play a major role in publ...

Eligibility Criteria

Inclusion

  • Subject is capable of understanding and complying with the protocol
  • Good physical and mental health (normal physical exam, ECG, blood and urine chemistries, including absences of history or laboratory evidence of diabetes)
  • Body Mass Index between 18-30, inclusive
  • Age 21-50 years (age will be verified by driver's license or other valid form of identification)
  • Have used alcohol, on average, between 5-15 drinks per week over the past 6 months.
  • Have a stable living situation with current postal address

Exclusion

  • Meets criteria for current alcohol or substance use disorders (Past alcohol or substance use disorders greater than 3 years ago is acceptable)
  • Concurrent diagnosis of Axis I disorder
  • bMaintained on an antipsychotic or antidepressant medication; taking prescription medications except certain short-term anti-fungal agents and some tropical creams for dermal conditions
  • Heavy alcohol drinkers (greater than 15 drinks per week)
  • Tobacco use greater than 5 cigarettes per day
  • History of major head trauma resulting in cognitive impairment or history of seizure disorder
  • Heavy caffeine use (greater than 500 mg on a regular daily basis)
  • Subject has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT) \> 3x the upper limit of normal
  • For female volunteers, a positive pregnancy test

Key Trial Info

Start Date :

January 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2024

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT03242161

Start Date

January 1 2018

End Date

April 30 2024

Last Update

January 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

McLean Hospital

Belmont, Massachusetts, United States, 02478